ICN

Bausch Health Companies Inc., formerly known as ICN Pharmaceuticals and later Valeant Pharmaceuticals, is a global specialty pharmaceutical company headquartered in Laval, Canada. The company's legacy is defined by its founding as ICN in 1960 and its development of the landmark antiviral drug ribavirin (Virazole). Today, Bausch Health focuses on core therapeutic areas including gastroenterology, dermatology, and hepatology, operating through major divisions such as Salix Pharmaceuticals and Ortho Dermatologics. Its leading commercial products include Xifaxan for irritable bowel syndrome and hepatic encephalopathy, and Relistor for opioid-induced constipation. The company maintains a robust pipeline with late-stage candidates like amiselimod for ulcerative colitis and next-generation rifaximin formulations.